Cleveland

CPL Acquires Ohio-Based Firm to Expand Services into the Midwest

Retrieved on: 
Monday, October 30, 2023
Education, Cuyahoga Community College, MPA, Oberlin College, Acquisition, Creativity, AIA, CPL, City, Culture, Public sector, Cleveland, Kent State University, NCARB, Semen Makovich, University Hospitals Cleveland Medical Center, MetroHealth, Cleveland Clinic, Management

The move combines MPA's portfolio and knowledge base in healthcare, higher education, and the public sector with CPL's innovative design approach and client-service expertise.

Key Points: 
  • The move combines MPA's portfolio and knowledge base in healthcare, higher education, and the public sector with CPL's innovative design approach and client-service expertise.
  • "Culture is key and MPA brings the same energy and values to their business and clients as CPL.
  • "When seeking a partner, our goal was to find a firm that shares a common set of core principles and mission-driven values," said Don Rerko, AIA, NCARB, president, MPA.
  • "The opportunity to join the CPL team will allow us to broaden our scope and scale our services more quickly to meet the growing needs of clients."

Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors

Retrieved on: 
Wednesday, October 11, 2023
Sheba Medical Center, AI, Internet, Intel Capital, Biotechnology, Medicine, Cancer, Immunotherapy, Cleveland, Longevity, Drug discovery, Business development, High tech, Cleveland Clinic, Pharmaceutical industry

LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors.

Key Points: 
  • LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors.
  • Beyond this board position, Mr. Miller will also take on an advisory role, contributing to the company's strategy and business development efforts.
  • Renovaro Biosciences has recently signed a definitive agreement to combine with GEDiCube, a UK-based medical AI company specializing in early detection and remissions of cancer, and expedited drug discovery ( Renovaro Press Release ) ( GEDiCube press release ).
  • I am delighted to have the opportunity to assist the company as a board member and an advisor working closely with the company’s leadership team,” said Avram Miller.

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Retrieved on: 
Thursday, October 5, 2023
III, Partnership, MBA, Cleveland Clinic, Organization, Risk, Safety, Survival, Disease, DSMB, Therapy, AAV, Cleveland, MYBPC3, Clinical trial, SAN, ClinicalTrials.gov, Relaxation, Human, HCM, Patient, Facial muscles, Pharmaceutical industry, Medical device

The working MYBPC3 gene is intended to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle.

Key Points: 
  • The working MYBPC3 gene is intended to restore normal levels of myosin-binding protein, which regulates the contraction and relaxation of the heart muscle.
  • The MyPeak-1 clinical trial will be conducted at up to twelve leading U.S. centers specializing in HCM care.
  • The first site that is actively recruiting patients is the Hypertrophic Cardiomyopathy Center at the Cleveland Clinic, Cleveland, Ohio.
  • To learn more about gene therapy for HCM and participation in the MyPeak-1 study, please visit HCMStudies.com or ClinicalTrials.gov (NCT05836259) .

Transurban and Partners Demonstrate the Future of Safer Travel with Connected Autonomous Vehicles on Virginia Express Lanes

Retrieved on: 
Monday, October 16, 2023
Public Policy, Government, Transportation, State, Local, Travel, Automotive, Trucking, General Automotive, Transport, Partnership, Express, Transurban, Commonwealth, VDOT, Safety, ADS, Cleveland, Law enforcement, USDOT, CAMP, Virginia Department of Transportation, CAV, Silicon, Research, Road

Transurban and our partners know we must continually innovate to keep travelers safer as technology enables the next generation of transportation,” said Mike Discenza, Acting President, Transurban North America.

Key Points: 
  • Transurban and our partners know we must continually innovate to keep travelers safer as technology enables the next generation of transportation,” said Mike Discenza, Acting President, Transurban North America.
  • “Smart roads, like Transurban’s Express Lanes, are leading the way in integrated infrastructure technology—and we are just getting started.
  • The trials and demonstrations on the 395 Express Lanes mark the twelfth such study, following previous research on fully and partially autonomous vehicles and driverless heavy trucking.
  • A new partnership with Silicon Valley’s Plus was launched earlier this year to further autonomous trucking research in Australia.

Dr. Karin B. Cesario Joins Peak Gastroenterology Associates

Retrieved on: 
Friday, October 13, 2023
Managed Care, General Health, Health, Other Health, University of Colorado School of Medicine, Peak, Cleveland Clinic, University, OH, Cleveland, GCP, Fellow, American Gastroenterological Association, Patient, Gastroenterology, Hospital

Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today announced Karin B. Cesario, M.D.

Key Points: 
  • Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today announced Karin B. Cesario, M.D.
  • “We are absolutely thrilled to have Dr. Cesario join the Peak team,” said Dr. Prashant Krishnan, a Peak care provider and Gastro Care Partners’ Chief Medical Officer.
  • Peak is the fastest growing and largest gastroenterology practice in Southern Colorado.
  • Peak is a preferred partner of Gastro Care Partners.

Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Medical Devices, Hospitals, Health, Oncology, Annual general meeting, Lung cancer, Neoplasm, Biomarker, American College of Chest Physicians, NSCLC, American College, PCR, NGS, DNA, AUC, MPH, Disease, Lung, Patient, Sightline (architecture), National Lung Screening Trial, Cleveland, Liquid biopsy, Cleveland Clinic, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced recent updates in its lung cancer detection program for early-stage disease.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced recent updates in its lung cancer detection program for early-stage disease.
  • Additionally, the company strengthened its leadership team with the appointment of Mathias Ehrich, M.D., as its chief scientific officer.
  • Earlier this year, the company announced that the Nucleix EpiCheck® Lung Atlas, which utilizes next-generation sequencing (NGS) and is focused on stage I disease, had identified many promising, novel biomarkers for the early detection of lung cancer.
  • “Over the past few months, we’ve made incredible progress on our lung cancer program, having recently premiered data on the Nucleix EpiCheck Lung Atlas and enrolled more than 4,000 patients in the Sightline study,” said Chris Hibberd, chief executive officer of Nucleix.

Hartlepool: Victim named in anti-terrorism murder investigation

Retrieved on: 
Monday, October 16, 2023
Cleveland Police, Cleveland, BBC, Injury, National Counter Terrorism Policing Network, Family, Flower, Death, Man, BBC North East and Cumbria, Friends, Private investigator, General store, Nightclub

Hartlepool: Victim named in anti-terrorism murder investigation

Key Points: 
  • Hartlepool: Victim named in anti-terrorism murder investigation
    - Published
    A man has died and another remains in hospital after an attack that is being investigated by counter-terrorism police.
  • Another man had already been discovered at a house in nearby Wharton Terrace, also in Hartlepool.
  • A man, 44, was arrested on suspicion of murder and attempted murder.
  • The surviving victim, whose age has not been released, has been taken to hospital with injuries that are not believed to be life-threatening.

33 Semifinalists Vie for $1 Million Yass Prize

Retrieved on: 
Wednesday, October 11, 2023
CER, Parent, Multimedia, Partnership, Science and Technology Education Innovation Center, Education reform, Student, Pulitzer, The Beach Boys, Education, Cleveland Museum of Art, Center for Education Reform, Reward, Rock, Yass, Accelerator, Rock & Roll Hall of Fame Covers EP, Movement, Beach, Cleveland, Politics, Journalism, Celebration, Pharmaceutical industry, Nursing, Management, Tutoring, Art

WASHINGTON, Oct. 11, 2023 /PRNewswire/ -- Following the inaugural Yass Summit, held October 10 at the Rock & Roll Hall of Fame in Cleveland, a diverse group of 33 Semifinalists for the $1 million Yass Prize were announced, while a major new organization was unveiled to meet the needs of a growing movement of transformational education providers. 

Key Points: 
  • The new Yass Center for Education will combine the forces of the Yass Prize and CER into a new national force.
  • This year's Yass Prize Semifinalists will be the guiding light for the renewed mission of the Yass Center.
  • The prestigious $1 million Yass Prize is considered the Pulitzer of Education Innovation, according to Forbes Chief Content Editor, Randall Lane.
  • In conjunction with the $1 million Yass Prize, the STOP Awards Initiative will distribute nearly $20 million in 2023.

Dr. Susan Kleiner Joins Electrolyte Boost as Chief Science Officer

Retrieved on: 
Tuesday, October 10, 2023
Storm, Health, New Power, Knowledge, Olympian, Cleveland, International Arctic Science Committee, Mood (psychology), Miami Heat, Communication, Market, Book, LOS, Committee, Academy of Nutrition and Dietetics, Hiram College, Cavalier, Electrolyte, Farmer, Seattle Storm, History of the Miami Heat, Athlete, Cleveland Browns, Research, FACN, Management, Woman, RD, Biology, Seattle Seahawks, Seattle SuperSonics, Medicine, Science

LOS ANGELES, Oct. 10, 2023 /PRNewswire/ -- Electrolyte Boost, a leading provider of innovative electrolyte and hydration products, today announced the appointment of Dr. Susan Kleiner as Chief Science Officer. Dr. Kleiner, a world-renowned expert in the field of nutrition and sports performance, will bring her unparalleled knowledge and experience to guide the strategic direction and product development of Electrolyte Boost.

Key Points: 
  • Doctor of Nutrition Further Validates the Electrolyte Boost Product Offering, Demonstrating its Value to the Market
    LOS ANGELES, Oct. 10, 2023 /PRNewswire/ -- Electrolyte Boost , a leading provider of innovative electrolyte and hydration products, today announced the appointment of Dr. Susan Kleiner as Chief Science Officer.
  • "We are thrilled to welcome Susan to our team," said Gary Kleinman, Founder and CEO of Electrolyte Boost.
  • "I am honored to be a part of the Electrolyte Boost team and contribute to their mission of revolutionizing the electrolyte industry," added Kleiner.
  • For more information about Dr. Kleiner, check out her LinkedIn profile: Dr. Susan Kleiner

Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing

Retrieved on: 
Thursday, October 5, 2023
Cleveland, Multimedia, NYSE, Doctor of Philosophy, Quest Diagnostics, Quest, Kidney disease, ESRD, Insurance, Transport, Dialysis, DGX, Patient, Atmosphere, Medical device, Newai

LITTLETON, Colo., Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).

Key Points: 
  • LITTLETON, Colo., Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).
  • Under the terms of the agreement, Neway will utilize the extensive lab network of Quest Diagnostics to provide local dialysis laboratory testing services with typically next-day results after arrival at a Quest Diagnostics laboratory.
  • By utilizing Quest's distributed lab network, Neway and its affiliated dialysis centers and their patients will experience faster testing and results reporting and lower transportation costs.
  • "Working together with Neway, we will address these challenges and expedite test results while maintaining the highest level of quality for patients with ESRD."